Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Shattuck Labs, Inc. STTK

Healthcare — Biotechnology
Cash Flow Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years ,
Insider Buys alert about insiders buying in the last 12 month

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total buys
0.25
Total sells
0.59
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — 1 — — —
Sell — — — — — — — 2 2 1 — —
Insider Ownership
33.56%

Capital & Financial Ratios

Market Cap
587.13
Revenue
5.61
Net Income
(52.57)
Free Cash Flow
(41.24)
Net Debt
(208.30)
Current Ratio
27.59
Debt/Equity
0.00
P/E ratio
0.00
P/S ratio
139.13
P/B ratio
3.69
Past 5Y EPS Growth
(20.93%)
This Y EPS Growth
29.57%
Next Y EPS Growth
(8.36%)
Next 5Y EPS Growth
4.78%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 130.63 72.99 78.07 208.30
Receivables — — — —
Inventory — — — —
Other — — — —
143.22 79.22 82.48 213.27
2023 2024 2025 Q'26
Payables 1.59 2.42 2.10 3.94
ST’ Debt — — — —
Other — — — —
11.45 8.92 7.05 7.73
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 — — — —
—
’25 — — 1.00 —
1.00
’24 1.12 1.61 3.00 0.00
5.72
’23 0.06 0.20 0.69 0.71
1.66
’22 — 0.05 0.21 0.39
0.65
’21 2.27 (4.23) 1.90 30.08
30.02
’20 2.98 3.18 2.44 1.34
9.93
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (13.42) (10.18) — —
—
’25 (12.03) (10.43) (8.93) (8.49)
(39.88)
’24 (16.16) (10.92) (16.07) (17.37)
(60.51)
’23 (26.46) (18.62) (16.73) (19.42)
(81.23)
’22 (26.28) (16.32) (28.06) (23.84)
(94.50)
’21 (11.07) (14.34) (12.99) (18.72)
(57.12)
’20 (10.45) 2.19 (11.35) (14.04)
(33.66)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (13.42) (10.33) — —
—
’25 (12.03) (10.43) (9.00) (8.49)
(39.95)
’24 (16.16) (10.93) (16.11) (17.37)
(60.57)
’23 (26.54) (18.91) (16.75) (19.44)
(81.63)
’22 (28.76) (24.00) (28.81) (24.43)
(106.01)
’21 (13.71) (16.67) (13.96) (20.71)
(65.04)
’20 (10.56) 1.87 (11.45) (14.24)
(34.39)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (0.13) (0.12) — —
—
’25 (0.27) (0.24) (0.14) (0.12)
(0.70)
’24 (0.37) (0.42) (0.33) (0.37)
(1.49)
’23 (0.49) (0.50) (0.65) (0.41)
(2.05)
’22 (0.58) (0.65) (0.58) (0.60)
(2.41)
’21 (0.28) (0.56) (0.41) 0.18
(1.07)
’20 (0.16) — (1.54) (0.31)
(2.36)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡‡ ‡‡‡‡ 1.85 1.33 0.94 0.69 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡‡ 9.46 7.77 11.76 3.70 — — —
High Price
— — — — ‡‡‡‡ ‡‡‡‡ 105 75 44 40 — — —
Employees
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.01 0.02 0.13 0.03 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.65 1.66 5.72 1.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 100.00% 100.00% 100.00% 100.00% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (101.94) (87.30) (75.41) (48.81) — — —
EBT
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (15,635.74%) (5,268.44%) (1,318.13%) (4,880.90%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (101.94) (87.30) (75.41) (48.81) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.44 2.56 1.68 3.24 — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.02 0.04 0.11 0.01 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.41) (2.05) (1.49) (0.70) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.23) (1.91) (1.19) (0.57) — — —
Cash Flow/Sh
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.27) (0.01) 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2.50) (1.92) (1.19) (0.57) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.16 3.40 1.57 1.18 — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 42.38 42.60 50.76 69.59 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
PE Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.45 194.36 10.74 45.31 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.60 2.23 0.77 3.08 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.64) 118.18 (1.26) 32.16 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.48 (2.40) 0.12 (4.51) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (94.50) (81.23) (60.51) (39.88) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.51) (0.41) (0.06) (0.07) — — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (106.01) (81.63) (60.57) (39.95) ‡‡‡‡‡ — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 159.62 131.77 70.30 75.42 — — —
Working Cap'
— — — — — — 4.90 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (156.38) (130.62) (72.99) (78.06) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 176.16 144.71 79.63 82.39 — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (40.46%) (47.85%) (60.18%) (53.61%) — — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡‡ (326.49%) (408.19%) (758.46%) (744.34%) — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (45.52%) (54.41%) (67.23%) (60.25%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Shattuck Labs (STTK), a clinical-stage biotech pioneering bifunctional fusion proteins for immuno-oncology and infectious diseases, has endured extreme volatility since its 2020 IPO, plummeting over 95% from $60 peaks amid clinical setbacks, revenue collapses, and relentless cash burn. Revenues surged to $30 million in 2021 on collaboration milestones but cratered 98% in 2022, with modest 2024 recovery to $5.72 million overshadowed by stagnant forecasts and 58% headcount cuts signaling survival mode. Yet, aggressive insider buying—directors snapping up over 12 million shares worth $10.9 million in August 2025—hints at conviction in upcoming pipeline catalysts like Phase 1/2 data for lead asset SL-1726.

Profitability remains dire, with annual losses exceeding $75 million, negative returns, and just 12-18 months of cash runway from a $73 million net cash position, pressuring potential dilution. Valuation metrics scream distress: PB at 0.77x, EV/Sales in negative territory, mirroring biotech bust cycles. Analyst targets reflect cautious optimism, with a mean implying 30% upside and highs at 290%, betting on trial successes amid macro risks and competition.

STTK’s fate pivots on derisking its ARC platform for breakthroughs or M&A appeal, evoking past biotech turnarounds like Geron—offering high-reward potential for patient investors, but demanding flawless execution in a unforgiving sector.

Read full commentary →

Shattuck Labs, Inc. (STTK) Latest News

News by impact score

Fine-tune

11 Aug

3 , 6:15 AM
Shattuck Labs reported second quarter 2026 financial results and recent business highlights. Quarterly financial results and business updates can shift near-term valuation and sentiment but rarely redefine long-term trajectory.

10 Jun

3 GlobeNewswire, 12:21 AM
Shattuck Labs priced a $75 million public offering. $75 million public offering supplies operating capital but dilutes shareholders and pressures near-term stock price.

9 Jun

3 GlobeNewswire, 4:18 PM
Shattuck Labs, Inc. (STTK) announces a proposed public offering of common stock to raise capital. Proposed public offering signals potential share dilution that may pressure near-term stock valuation while funding operations.

8 Jun

4 GlobeNewswire, 6:00 AM
Shattuck Labs announces Phase 1 results for SL-325. Phase 1 results for SL-325 mark a key clinical milestone that can shift pipeline outlook and investor sentiment.

5 Jun

3 GlobeNewswire, 4:05 PM
Shattuck Labs schedules investor call and webcast on June 8 to present Phase 1 clinical data for SL-325 DR3 blocking antibody and provide pipeline update. Phase 1 data release for novel antibody candidate can moderately shift investor sentiment toward pipeline progress.

7 May

3 GlobeNewswire, 6:15 AM
Shattuck Labs, Inc. (STTK) reported first quarter 2026 financial results and recent business highlights. Quarterly financial results and business highlights affect financial performance and investor sentiment.

1 May

4 , 4:20 PM
Shattuck Labs, Inc. reported its first quarter 2025 financial results, highlighting a cash balance of approximately $60.9 million, expected to fund operations into 2027. The company is advancing its SL-325 program, with an IND filing anticipated in Q3 2025 and a Phase 1 clinical trial set to begin in the same quarter. R&D expenses decreased to $9.9 million, while the net loss narrowed to $13.7 million. Shattuck continues to develop preclinical bispecific antibodies targeting the DR3/TL1A pathway for inflammatory bowel disease (IBD). Recent presentations at healthcare conferences showcased the promising safety profile of SL-325 in preclinical studies. The anticipated IND filing and Phase 1 trial initiation for SL-325 represent significant strategic moves that could alter the company's trajectory and investor sentiment.

3 Insider Monkey, 4:17 AM
Cantor Fitzgerald initiates coverage of Shattuck Labs (STTK). Brokerage initiation boosts analyst coverage and market visibility for STTK.

6 Mar

4 www.fool.com, 5:02 PM
Shattuck Labs, Inc. (STTK) stock soared more than 53% higher this week amid positive developments driving investor enthusiasm. A 53% weekly stock surge reflects major positive catalysts that could significantly boost future market performance and investor sentiment.

5 Mar

3 GlobeNewswire, 6:15 AM
Shattuck Labs, Inc. (STTK) reported fourth quarter and full-year 2025 financial results alongside recent business highlights. Quarterly financial results and business highlights affect key financial performance and investor sentiment but are routine disclosures.

6 Feb

3 GlobeNewswire, 8:30 AM
Shattuck Labs, Inc. (STTK) will participate in the upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium. The event will showcase the company's innovative approaches in immunology and provide insights into its research and development efforts. Participation in a symposium can enhance visibility and networking opportunities, potentially influencing future collaborations and market perception.

5 Jan

4 www.fool.com, 10:50 PM
Shattuck Labs, Inc. experienced a significant stock surge in December, driven by positive developments in its clinical trials and promising data regarding its innovative therapies. The company reported advancements in its pipeline, particularly in its lead product candidates, which garnered investor interest and confidence. This momentum reflects a growing optimism about the company's potential to address unmet medical needs and enhance its market position. Positive clinical trial results and advancements in product candidates are likely to significantly impact future performance and investor sentiment.

4 Simply Wall St., 8:13 AM
Insiders at Shattuck Labs, Inc. (STTK) have made significant investments in the company, signaling positive sentiment and confidence in its future prospects. This insider activity is often viewed as a bullish indicator, suggesting that those with the most knowledge of the company's operations believe in its potential for growth. The investments come at a time when the company is navigating its strategic initiatives and market positioning. Insider investments typically indicate strong confidence in the company's future, which can significantly influence market sentiment and performance.

29 Nov

4 Insider MonkeyInsider MonkeyInsider MonkeyInsider MonkeyTipRanksInsider MonkeyInsider Monkey, 1:26 AM
Analysts express optimism regarding Shattuck Labs, Inc. (STTK) due to advancements in SL-325 and the company's earlier Q3 2025 results. The positive sentiment reflects confidence in the company's ongoing projects and potential for future growth. Progress on SL-325 and favorable Q3 results indicate significant potential for future performance and investor sentiment.

6 Nov

3 GlobeNewswire, 4:30 PM
Shattuck Labs, Inc. (STTK) reported its financial results for the third quarter of 2025, highlighting key business developments and performance metrics. The company showcased advancements in its product pipeline and strategic initiatives aimed at enhancing its market position. Financial figures indicated growth in revenue and investments in research and development, reflecting a commitment to innovation. Management provided insights into future plans and expectations, emphasizing the potential for continued progress in the upcoming quarters. The financial results and strategic initiatives may moderately influence Shattuck Labs' competitive positioning and market performance.

8 Oct

4 ZacksZacksZacksZacksZacksZacksZacksZacks, 12:00 PM
Shattuck Labs, Inc. (STTK) is identified as a strong momentum stock due to its innovative approach in the biopharmaceutical sector, particularly its proprietary platforms that enhance the efficacy of immunotherapies. The company has shown promising clinical trial results, which have positively influenced investor sentiment and stock performance. Analysts suggest that the ongoing developments and potential product launches could lead to significant growth, making it an attractive buy for investors looking for momentum stocks. Promising clinical trial results and potential product launches are likely to significantly impact the company's future performance and investor sentiment.

2 Oct

3 GlobeNewswire, 7:51 AM
Shattuck Labs, Inc. (STTK) announced its participation in the upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel, where company executives will discuss their innovative approaches and advancements in the field. This event aims to enhance investor understanding of Shattuck's strategic direction and product pipeline. Participation in the KOL panel may enhance investor sentiment and provide insights into the company's strategic initiatives.

19 Sep

3 , 9:55 AM
Shattuck Labs, Inc. (STTK) has recently experienced a 'Golden Cross' in its stock chart, indicating a potential bullish trend as the short-term moving average crosses above the long-term moving average. This technical signal has attracted attention from investors, suggesting a possible upward momentum in the stock price. Analysts are evaluating whether this trend could lead to sustained growth and improved market performance for the company, particularly in light of its ongoing projects and market positioning. The Golden Cross indicates a potential positive trend, but its long-term impact on Shattuck Labs' performance remains uncertain.

8 Sep

4 Zacks, 5:09 PM
Shattuck Labs, Inc. (STTK) has been upgraded to a 'Buy' rating by analysts, indicating a positive outlook for the stock. This upgrade reflects confidence in the company's growth potential and strategic direction, which may attract more investors and enhance market sentiment. The upgrade is expected to influence STTK's stock performance positively in the near term. The upgrade to 'Buy' suggests significant positive sentiment and potential for improved market performance.

4 Sep

4 Simply Wall St., 8:05 AM
Shattuck Labs, Inc. (STTK) is highlighted as a top penny stock to watch in September 2025 due to its innovative approaches in the biopharmaceutical sector. The company is focusing on developing its proprietary platforms for cancer therapies, which could enhance its market position. Investors are encouraged to monitor STTK for potential growth opportunities as it navigates the competitive landscape and regulatory environment. Significant strategic moves in cancer therapy development could alter the company's trajectory and investor sentiment.

26 Aug

4 GlobeNewswire, 6:30 AM
Shattuck Labs, Inc. has successfully closed a private placement of up to $103 million, aimed at strengthening its financial position. Additionally, the company announced new appointments to its Board of Directors, which may enhance its governance and strategic direction. The private placement and board appointments are significant strategic moves that could positively influence the company's future performance and investor sentiment.

21 Aug

4 , 11:12 AM
Shattuck Labs, Inc. announced that its Investigational New Drug Application (IND) for SL-325 has become effective. This marks a significant step in the development of SL-325, a potential treatment aimed at addressing specific medical conditions. The company is now positioned to advance clinical trials and further evaluate the drug's safety and efficacy. The effective IND for SL-325 is a major regulatory milestone that could significantly impact Shattuck Labs' future product development and market positioning.

4 , 10:17 AM
Shattuck Labs, Inc. announced that the Investigational New Drug (IND) application for SL-325, a treatment for Inflammatory Bowel Disease, is now in effect. This marks a significant step in the development of SL-325, which aims to address unmet medical needs in patients suffering from this condition. The approval of the IND for SL-325 represents a significant advancement in Shattuck Labs' product pipeline and could enhance its market position in the treatment of Inflammatory Bowel Disease.

14 Aug

4 GlobeNewswire, 6:30 AM
Shattuck Labs, Inc. (STTK) reported its financial results for the second quarter of 2025, highlighting key business developments and performance metrics. The company showcased advancements in its product pipeline and strategic initiatives aimed at enhancing its market position. Financial figures indicated growth in revenue and investments in research and development, reflecting a commitment to innovation and expansion. Management provided insights into future plans and expectations, emphasizing ongoing efforts to strengthen the company's competitive edge in the biotechnology sector. Significant advancements in product development and strategic initiatives are likely to impact future performance and investor sentiment.

5 Aug

4 GlobeNewswire, 6:30 AM
Shattuck Labs, Inc. announced an oversubscribed private placement of up to approximately $103 million. The financing is expected to support the company's ongoing development of its proprietary platforms and product candidates. The placement reflects strong investor interest and confidence in Shattuck's strategic direction and growth potential. The oversubscribed private placement indicates significant investor confidence and provides substantial funding for strategic initiatives.

3 , 10:30 AM
Shattuck Labs, Inc. (STTK) has been highlighted as one of the most active stocks in the market, indicating increased trading volume and investor interest. The company's recent developments and market activities have drawn attention, reflecting potential shifts in investor sentiment and market dynamics. Increased trading activity suggests a moderately noticeable influence on market sentiment and potential financial performance.

2 Jul

3 , 7:00 AM
Shattuck Labs, Inc. (STTK) announced its participation in the upcoming Leerink Partners Therapeutics Forum focused on Immunology & Inflammation (I&I) and Metabolism. The event will provide a platform for the company to showcase its innovative approaches and pipeline developments in these therapeutic areas. Participation in a prominent forum may enhance visibility and networking opportunities, potentially influencing future collaborations and market sentiment.

13 Jun

3 , 6:33 AM
Shattuck Labs, Inc. is facing scrutiny over its cash burn situation as it navigates financial challenges. The company has been investing heavily in its pipeline, which raises concerns about sustainability and future funding needs. Analysts are closely monitoring its cash reserves and operational efficiency to assess potential impacts on growth and market performance. The current cash burn rate could influence investor sentiment and strategic decisions moving forward. The cash burn situation may affect financial performance and investor sentiment, but its overall impact is expected to be somewhat limited.

8 Apr

3 , 7:05 AM
Shattuck Labs, Inc. (STTK) is highlighted as one of three promising penny stocks with market capitalizations under $300 million. The company focuses on innovative therapies for cancer and autoimmune diseases, leveraging its proprietary technology platform. Investors are encouraged to consider STTK due to its potential for growth and the strategic direction it is taking in the biotech sector. The company's focus on innovative therapies may moderately influence its financial performance and competitive positioning.

28 Mar

3 , 7:32 AM
Shattuck Labs, Inc. (STTK) reported its full-year 2024 earnings, which fell short of market expectations. The company faced challenges that impacted its financial performance, leading to a decline in stock value. Analysts had anticipated stronger results, but the actual figures revealed weaknesses in revenue generation and operational efficiency. Investors reacted negatively to the news, reflecting concerns about the company's future growth prospects. Earnings miss indicates potential challenges in financial performance and market sentiment, but not a complete shift in trajectory.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us